These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8176479)

  • 1. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels.
    Shih LB; Thorpe SR; Griffiths GL; Diril H; Ong GL; Hansen HJ; Goldenberg DM; Mattes MJ
    J Nucl Med; 1994 May; 35(5):899-908. PubMed ID: 8176479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.
    Stein R; Goldenberg DM; Thorpe SR; Basu A; Mattes MJ
    Cancer Res; 1995 Jul; 55(14):3132-9. PubMed ID: 7606734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.
    Press OW; Shan D; Howell-Clark J; Eary J; Appelbaum FR; Matthews D; King DJ; Haines AM; Hamann P; Hinman L; Shochat D; Bernstein ID
    Cancer Res; 1996 May; 56(9):2123-9. PubMed ID: 8616860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells.
    Mattes MJ; Griffiths GL; Diril H; Goldenberg DM; Ong GL; Shih LB
    Cancer; 1994 Feb; 73(3 Suppl):787-93. PubMed ID: 8306261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell cytotoxicity with radiolabeled antibodies.
    Ong GL; Elsamra SE; Goldenberg DM; Mattes MJ
    Clin Cancer Res; 2001 Jan; 7(1):192-201. PubMed ID: 11205908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.
    Yao Z; Garmestani K; Wong KJ; Park LS; Dadachova E; Yordanov A; Waldmann TA; Eckelman WC; Paik CH; Carrasquillo JA
    J Nucl Med; 2001 Oct; 42(10):1538-44. PubMed ID: 11585870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved iodine radiolabels for monoclonal antibody therapy.
    Stein R; Govindan SV; Mattes MJ; Chen S; Reed L; Newsome G; McBride BJ; Griffiths GL; Hansen HJ; Goldenberg DM
    Cancer Res; 2003 Jan; 63(1):111-8. PubMed ID: 12517786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies.
    Gestin JF; Loussouarn A; Bardiès M; Gautherot E; Gruaz-Guyon A; Saï-Maurel C; Barbet J; Curtet C; Chatal JF; Faivre-Chauvet A
    J Nucl Med; 2001 Jan; 42(1):146-53. PubMed ID: 11197965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells.
    Geissler F; Anderson SK; Venkatesan P; Press O
    Cancer Res; 1992 May; 52(10):2907-15. PubMed ID: 1581908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of 4 radionuclides conjugated to antibodies for single-cell kill.
    Michel RB; Brechbiel MW; Mattes MJ
    J Nucl Med; 2003 Apr; 44(4):632-40. PubMed ID: 12679410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fate of antibodies bound to the surface of tumor cells in vitro.
    Kyriakos RJ; Shih LB; Ong GL; Patel K; Goldenberg DM; Mattes MJ
    Cancer Res; 1992 Feb; 52(4):835-42. PubMed ID: 1737345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
    Sharkey RM; Behr TM; Mattes MJ; Stein R; Griffiths GL; Shih LB; Hansen HJ; Blumenthal RD; Dunn RM; Juweid ME; Goldenberg DM
    Cancer Immunol Immunother; 1997 May; 44(3):179-88. PubMed ID: 9191878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
    van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
    J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response.
    Jacobs AJ; Fer M; Su FM; Breitz H; Thompson J; Goodgold H; Cain J; Heaps J; Weiden P
    Obstet Gynecol; 1993 Oct; 82(4 Pt 1):586-93. PubMed ID: 8377986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro toxicity of A-431 carcinoma cells with antibodies to epidermal growth factor receptor and epithelial glycoprotein-1 conjugated to radionuclides emitting low-energy electrons.
    Michel RB; Castillo ME; Andrews PM; Mattes MJ
    Clin Cancer Res; 2004 Sep; 10(17):5957-66. PubMed ID: 15355929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
    van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody localization to B-cell lymphoma xenografts in immunodeficient mice: importance of using residualizing radiolabels.
    Michel RB; Ochakovskaya R; Mattes MJ
    Clin Cancer Res; 2002 Aug; 8(8):2632-9. PubMed ID: 12171895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.